Disease · MONDO_0012004
parathyroid gland carcinoma
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. parathyroid gland carcinoma. Diseases, record MONDO_0012004. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0012004
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
adenocarcinoma of parathyroid, adenocarcinoma of parathyroid gland, adenocarcinoma of the parathyroid, adenocarcinoma of the parathyroid gland, cancer of parathyroid gland, cancer of the parathyroid gland, carcinoma of parathyroid, carcinoma of parathyroid gland, carcinoma of the parathyroid, carcinoma of the parathyroid gland, malignant neoplasm of parathyroid gland, malignant neoplasm of the parathyroid, parathyroid adenocarcinoma, parathyroid cancer, parathyroid carcinoma, parathyroid gland adenocarcinoma, parathyroid gland cancer, parathyroid gland neoplasm, parathyroid neoplasm
- Open Targets
Drugs4
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CINACALCET | CHEMBL1201284 | Small molecule | Approval | EMA Human Drugs, at withdrawal | 3 | 1 | 1 | Drugs and targets |
| CINACALCET HYDROCHLORIDE | CHEMBL1200776 | Small molecule | Approval | DailyMed | 3 | 0 | 0 | Drugs and targets |
| EVOCALCET | CHEMBL4297621 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LUTETIUM OXODOTREOTIDE LU-177 | CHEMBL4297545 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets6
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CASR | Extracellular calcium-sensing receptor | 3 | Calcium sensing receptor positive allosteric modulator | Approval | https://conductscience.org/library/genes/846 | Drugs and targets |
| SSTR1 | Somatostatin receptor | 1 | Somatostatin receptor binding agent | Phase 2 | https://conductscience.org/library/genes/6751 | Drugs and targets |
| SSTR2 | Somatostatin receptor | 1 | Somatostatin receptor binding agent | Phase 2 | https://conductscience.org/library/genes/6752 | Drugs and targets |
| SSTR3 | Somatostatin receptor | 1 | Somatostatin receptor binding agent | Phase 2 | https://conductscience.org/library/genes/6753 | Drugs and targets |
| SSTR4 | Somatostatin receptor | 1 | Somatostatin receptor binding agent | Phase 2 | https://conductscience.org/library/genes/6754 | Drugs and targets |
| SSTR5 | Somatostatin receptor | 1 | Somatostatin receptor binding agent | Phase 2 | https://conductscience.org/library/genes/6755 | Drugs and targets |
Trials3
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03280264 | Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism | Phase 3 | 18 | 2021-05-27 | Parathyroid Carcinoma, Primary Hyperparathyroidism | EVOCALCET | Its record names the disease | ClinicalTrials.gov |
| NCT04106843 | Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers | Phase 2 | 0 | Locally Advanced Adrenal Gland Pheochromocytoma, Locally Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma, Metastatic Parathyroid Gland Carcinoma, Pituitary Gland Carcinoma, Somatostatin Receptor Positive, Stage III Thyroid Gland Medullary Carcinoma AJCC v8, Stage IV Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8, Unresectable Adrenal Gland Pheochromocytoma, Unresectable Paraganglioma | LUTETIUM OXODOTREOTIDE LU-177 | Its record names the disease | ClinicalTrials.gov | |
| NCT01460030 | An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism | Phase 3 | Parathyroid Carcinoma, Hypercalcemia, Primary Hyperparathyroidism | CINACALCET | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials0
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
None in this release.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0012004
GET https://conductscience.org/api/diseases/v1/MONDO_0012004/drugs